S100B Protein but Not 3-Nitrotyrosine Positively Correlates with Plasma Ammonia in Patients with Inherited Hyperammonemias: A New Promising Diagnostic Tool?
- PMID: 36983411
- PMCID: PMC10056255
- DOI: 10.3390/jcm12062411
S100B Protein but Not 3-Nitrotyrosine Positively Correlates with Plasma Ammonia in Patients with Inherited Hyperammonemias: A New Promising Diagnostic Tool?
Abstract
Individuals with inherited hyperammonemias often present developmental and intellectual deficiencies which are likely to be exaggerated by hyperammonemia episodes in long-term outcomes. In order to find a new, systemic marker common to the course of congenital hyperammonemias, we decided to measure the plasma level of S100 calcium-binding protein B (S100B), which is associated with cerebral impairment. Further, we analyzed three mechanistically diverged but linked with oxidative-nitrosative stress biochemical parameters: 3-nitrotyrosine (3-NT), a measure of plasma proteins' nitration; advanced oxidation protein products (AOPP), a measure of protein oxidation; and glutathione peroxidase (GPx) activity, a measure of anti-oxidative enzymatic capacity. The plasma biomarkers listed above were determined for the first time in congenital hyperammonemia. Also, the level of pro- and anti-inflammatory mediators (i.e., IL-12, IL-6, IL-8, TNF-α, IL-1β, and IL-10) and chemokines (IP-10, MCP-1, MIG, and RANTES) were quantified. S100B was positively correlated with plasma ammonia level, while noticeable levels of circulating 3-NT in some of the patients' plasma did not correlate with ammonia concentration. Overall, the linear correlation between ammonia and S100B but not standard oxidative stress-related markers offers a unique perspective for the future identification and monitoring of neurological deficits risk-linked with hyperammonemia episodes in patients with inherited hyperammonemias. The S100B measure may support the development of therapeutic targets and clinical monitoring in these disorders.
Keywords: 3-nitrotyrosine; S100B; ammonia; urea cycle disorders.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Clinical and biochemical aspects of primary and secondary hyperammonemic disorders.Arch Biochem Biophys. 2013 Aug 15;536(2):101-8. doi: 10.1016/j.abb.2013.04.009. Epub 2013 Apr 27. Arch Biochem Biophys. 2013. PMID: 23628343 Review.
-
The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis.J Physiol Pharmacol. 2019 Apr;70(2). doi: 10.26402/jpp.2019.2.04. Epub 2019 Jul 22. J Physiol Pharmacol. 2019. PMID: 31356182
-
Investigation on malondialdehyde, S100B, and advanced oxidation protein product levels in significant hyperbilirubinemia and the effect of intensive phototherapy on these parameters.Pediatr Neonatol. 2015 Apr;56(2):95-100. doi: 10.1016/j.pedneo.2014.06.006. Epub 2014 Sep 26. Pediatr Neonatol. 2015. PMID: 25261050
-
Inherited metabolic disorders in Pakistan: presentation, diagnosis and outcome of congenital hyperammonemias.J Pak Med Assoc. 1994 Oct;44(10):229-32. J Pak Med Assoc. 1994. PMID: 7815684
-
Hyperammonemia in urea cycle disorders: role of the nephrologist.Am J Kidney Dis. 2001 May;37(5):1069-80. doi: 10.1016/s0272-6386(05)80026-5. Am J Kidney Dis. 2001. PMID: 11325692 Review.
References
-
- Häberle J., Burlina A., Chakrapani A., Dixon M., Karall D., Lindner M., Mandel H., Martinelli D., Pintos-Morell G., Santer R., et al. Suggested Guidelines for the Diagnosis and Management of Urea Cycle Disorders: First Revision. J. Inherit. Metab. Dis. 2019;42:1192–1230. doi: 10.1002/jimd.12100. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous